Filtered By:
Condition: Thyroiditis
This page shows you your search results in order of relevance. This is page number 2.
Order by Relevance | Date
Total 23 results found since Jan 2013.
Risks and benefits of rituximab in the treatment of Hashimoto ’s encephalopathy in children: Two case reports and a mini-review
Hashimoto ’s encephalopathy was first described in adults by Lord Brain in 1966. 1 This rare syndrome denotes an association of encephalopathy with Hashimoto thyroiditis.2 The disease is characterized by a subacute onset of confusion with altered level of consciousness, seizures and myoclonus. It’s manife stations, however vary widely and coma, hallucinations, psychosis, headache, stroke like episodes, subacute cognitive decline and tremor have all been reported.3
Source: Pediatric Neurology - September 19, 2016 Category: Neurology Authors: A. Maas, K.P.J. Braun, K. Geleijns, F.E. Jansen, A. van Royen-Kerkof Tags: Review Article Source Type: research
Unique presentation of LHON/MELAS overlap syndrome caused by m.13046T > C in MTND5.
CONCLUSIONS: We describe a unique presentation of LHON/MELAS overlap syndrome resulting from a m.13046T>C mutation in a 12-year-old girl. In patients with sudden vision loss in which three of the most prevalent LHON mitochondrial mutations have been ruled out, molecular genetic examination should be extended to other mtDNA-encoded subunits of MTND5 complex I. Furthermore, atypical clinical presentations must be considered, even in well-described phenotypes.
PMID: 26894521 [PubMed - in process]
Source: Ophthalmic Genetics - November 3, 2016 Category: Opthalmology Tags: Ophthalmic Genet Source Type: research
Effects of short ‐term levothyroxine therapy on myocardial injuries in patients with severe overt hypothyroidism: Evidence from a cardiac MRI Study
ConclusionWe suggest that the negative effect induced by severe overt HT on the cardiovascular system can be significantly improved by restoring euthyroidism with short‐term levothyroxine therapy.Level of Evidence: 1J. Magn. Reson. Imaging 2017.
Source: Journal of Magnetic Resonance Imaging - March 21, 2017 Category: Radiology Authors: Xia Gao, Zhe Chen, Min Liu, Yu ‐Mei Jia, Ning Yang, Zhi Yao, Xiao‐Meng Feng, Yuan Xu, Guang Wang Tags: Original Research Source Type: research
Sex Difference of Radiation Response in Occupational and Accidental Exposure
Conclusion and Outlook
This review summarizes the data from major human studies on the health risks of radiation exposure and shows that sex can potentially influence the prolonged response to radiation exposure (Figure 1 and Tables 1, 2). These data suggest that long-term radiosensitivity in females is higher than that in males who receive a comparable dose of radiation. Our analysis of the literature agrees with the conclusions of the recent report on the Biological effects of ionizing radiation (BEIR VII) published in 2006 by the National Academy of Sciences (NAS), United States (National Research Council, 2006). The B...
Source: Frontiers in Genetics - May 2, 2019 Category: Genetics & Stem Cells Source Type: research
Oral tolerance: an updated review
Immunol Lett. 2022 Apr 5:S0165-2478(22)00041-4. doi: 10.1016/j.imlet.2022.03.007. Online ahead of print.ABSTRACTOral tolerance (OT) has classically been defined as the specific suppression of cellular and/or humoral immune responses to an antigen by prior administration of the antigen through the oral route. Multiple mechanisms have been proposed to explain the induction of OT including T cell clonal depletion and anergy when high doses of antigens are fed, and regulatory T (Treg) cell generation following oral administration of low and repeated doses of antigens. Oral antigen administration suppresses the immune response ...
Source: Immunology Letters - April 8, 2022 Category: Allergy & Immunology Authors: Rafael M Rezende Howard L Weiner Source Type: research
U.S. FDA Approves TECVAYLI ™ (teclistamab-cqyv), the First Bispecific T-cell Engager Antibody for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
HORSHAM, Pa., October 25, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) approved TECVAYLI™ (teclistamab-cqyv) for the treatment of adult patients with relapsed or refractory multiple myeloma, who previously received four or more prior lines of therapy, including a proteasome inhibitor, immunomodulatory drug and anti-CD38 monoclonal antibody.1 TECVAYLI™ is a first-in-class, bispecific T-cell engager antibody that is administered as a subcutaneous treatment.1 This off-the-shelf (or ready to use) therapy uses innovative science to ac...
Source: Johnson and Johnson - October 25, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
